BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1674947)

  • 1. The concept of the neuroleptic threshold: an update.
    Bitter I; Volavka J; Scheurer J
    J Clin Psychopharmacol; 1991 Feb; 11(1):28-33. PubMed ID: 1674947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The "neuroleptic threshold"--a review of the literature].
    Abraham D; Kissling W; Lauter H
    Psychiatr Prax; 1996 May; 23(3):109-16. PubMed ID: 8710999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study.
    McEvoy JP; Stiller RL; Farr R
    J Clin Psychopharmacol; 1986 Jun; 6(3):133-8. PubMed ID: 3711363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.
    Kinon BJ; Kane JM; Chakos M; Munne R
    Psychopharmacol Bull; 1993; 29(3):365-9. PubMed ID: 7907184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of neuroleptic psychopharmacology.
    Ortiz A; Gershon S
    J Clin Psychiatry; 1986 May; 47 Suppl():3-11. PubMed ID: 2871013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
    Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
    J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Incidence of the deficit form in refractory schizophrenia].
    Samuelian JC
    Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haase hermeneutics, or, the exegesis of the neuroleptic threshold.
    McEvoy JP; Kamaraju L; Nelson L
    J Clin Psychopharmacol; 1992 Feb; 12(1):64-5. PubMed ID: 1348062
    [No Abstract]   [Full Text] [Related]  

  • 10. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
    Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
    J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of neuroleptic dosage and extrapyramidal side effects on schizophrenic basic symptoms.
    Moritz S; Krausz M; Gottwalz E; Andresen B
    Compr Psychiatry; 2000; 41(4):284-8. PubMed ID: 10929797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neuroleptic large dose therapy of schizophrenias].
    Ungvári G; Pethö B
    Psychiatr Neurol Med Psychol (Leipz); 1981 Apr; 33(4):230-6. PubMed ID: 6114506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacologic approach to negative symptoms in schizophrenia].
    Jalenques I
    Encephale; 1995 Jun; 21 Spec No 3():35-40. PubMed ID: 7628340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum neuroleptic levels and extrapyramidal side effects in patients treated with amoxapine.
    Gaffney GR; Tune LE
    J Clin Psychiatry; 1985 Oct; 46(10):428-9. PubMed ID: 2864332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Testing basic visual functions in the evaluation of extrapyramidal side effects of antipsychotic agents].
    Kéri S; Antal A; Szekeres G; Szendi I; Kovács Z; Janka Z; Benedek G
    Orv Hetil; 1998 Feb; 139(5):235-8. PubMed ID: 9489377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen.
    Shriqui CL
    Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S38-48. PubMed ID: 8564916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcome.
    Heresco-Levy U; Greenberg D; Lerer B; Dasberg H; Brown WA
    J Clin Psychiatry; 1993 Feb; 54(2):59-62. PubMed ID: 8095259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Algorithm for treatment-refractory schizophrenia.
    Koshino Y
    Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S9-13. PubMed ID: 10560891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.